Organic Active Ingredients TRIZ Cases

Formula I compounds inhibit G3BP2 and ZEB1 proteins, reducing metastasis in breast and colorectal cancers.

Microbial biotransformation of nandrolone yields derivatives with leishmanicidal activity, addressing the lack of effective therapies for protozoal diseases.

Heterocyclic modifications enhance aqueous solubility and bypass P-glycoprotein efflux pumps, reducing neurotoxicity in melanoma and prostate cancer treatments.

Formula III thiazole derivatives target the Sec61 channel with high selectivity, resolving manufacturing and bioavailability trade-offs in secretion inhibition.

Polyphenols boost transmembrane proteins to fortify tight junctions, blocking harmful macromolecule passage and reducing immune activation.

Crystalline gepotidacin mesylate dihydrate and anhydrate forms enable high drug load oral solid formulations with improved tabletability.

Segmented core and coating resolve mucosal irritation while maintaining rapid disintegration.

Segmented unit doses with peelable seals enable accurate reconstitution, eliminating human error and ensuring long-term storage stability.

Formula I compounds inhibit Cathepsin K to treat osteoporosis by reducing bone degradation.

Pyridopyrimidine compounds act as ATP-competitive inhibitors to overcome partial mTORC1 blockade by Rapamycin.

Novel Lactiplantibacillus plantarum BNT_G401 strain biosynthesizes gamma-aminobutyric acid from monosodium glutamate in Curcuma longa extracts.

Phase transfer catalysis synthesizes dabigatran etexilate with high selectivity while eliminating acid waste generation.

Segmenting bicyclic scaffolds optimizes inhibitory activity against protein kinases, resolving insufficient efficacy in disubstituted pyrazine compounds.

Administering a Syk inhibitor blocks cytokine release to prevent severe CRS symptoms during cell therapy.

Quinuclidine compounds treat cognitive dysfunction in Gaucher disease by inhibiting glucosylceramide synthase, restoring neuronal connectivity.

Single-domain antibodies utilize natural endocytic pathways to access intracellular targets, eliminating the need for toxic exogenous delivery sequences.

Optimized particle size distribution in solid formulations enables immediate drug release, avoiding costly micronization processes.

Lipid nanoparticles encapsulate optimized mRNA ratios of CMV antigens to induce targeted immune responses while maintaining stability.

Dual EP2/EP4 receptor antagonism reactivates tumor immunity while avoiding cardiovascular side effects linked to COX inhibitors.

Endoplasmic reticulum stress inducers modify tumor cell culture to increase immune-activating proteins in secreted vesicles, resolving low immunogenicity.

Combined ROCK and JAK inhibitors reduce pulmonary fibrosis from coronavirus infections.

Merging RTK inhibition with microtubule destabilization into single bifunctional agents overcomes multidrug resistance while reducing systemic toxicity.

Bicyclic pyrimidine prodrugs improve bioavailability and half-life while reducing side effects from poor selectivity in erectile dysfunction treatments.

Crystal Form A of a propionamide derivative exhibits high purity and chemical stability through controlled solvent evaporation.

A poly-G sequence binds lysosome-associated membrane glycoproteins to direct target RNA into the lysosomal degradation pathway.

Novel terpene derivative PAR1 inhibitor reduces thrombotic risk while maintaining normal hemostasis.

Modifying thiolactomycin at positions 3 and 4 improves KAS enzyme binding, resolving the contradiction between synthesis ease and antibacterial activity.

NNMT antagonists inhibit nicotinamide N-methyltransferase expression to treat obesity and metabolic disorders.

Azetidine derivatives target the histamine H3 receptor to treat cognitive impairments while reducing side effects.

Introducing nucleic acids encoding Klotho protein into target cells increases endogenous protein levels, addressing insufficient treatment options for obesity.

A therapeutic oligomer composition uses peptide nucleic acid to regulate gene expression.

Recombinant fatty acid-modified elastin-like polypeptides self-assemble into micelles, increasing maximum tolerated dose of encapsulated drugs by up to 20-fold.

Engineered inverted terminal repeats prevent host cell protein binding to T-shaped hairpins, enabling persistent transgene expression.

Specific pyrazolopyridine compounds selectively inhibit CHK1 and CHK2, enhancing tumor cell death while sparing normal cells.

Small molecules bind to the TDP-43 protein to block nucleic acid interactions, addressing the lack of disease-modifying therapies for ALS and related disorders.

Imidazo[1,2-b]pyridazine derivatives suppress inflammation and itch by targeting tropomyosin-related kinase receptors in atopic dermatitis.

A solubilizer enables sustained release of poorly water-soluble therapeutic agents within an implantable reservoir.

Lipid organogelator matrices resist boiling solvent extraction, preventing dose dumping while maintaining controlled release kinetics.

Nanodiamond surfaces generate free radicals under ionizing radiation to enhance tumor cell sensitivity.

Substituted pyranonic acid derivatives reduce free fatty acids, glycerol, and triglycerides in plasma to treat metabolic syndrome.

Crystalline hydrates of a Janus kinase inhibitor replace hazardous reagents in synthesis while delivering stable solid state forms.

Formula I compounds inhibit B-Raf kinase activity to treat melanoma while minimizing toxicity to normal tissues.

Acetic and lactic acids dissolve imidazoquinolinamines within thermo-sensitive gels, resolving solubility limits while preventing systemic side effects.

2-pyridyl substituted imidazoles inhibit ALK5 receptors, blocking Smad phosphorylation to reduce fibrosis and cancer progression.

Incorporating citric acid establishes an acidic pH microenvironment that prevents alkaline degradation of clopidogrel in solid oral dosage forms.

An oral dissolving film adheres to gum tissue and releases anesthetic agents directly onto the mucous membrane.